Home > Boards > US Listed > Biotechs > Galera Therapeutics, Inc. (GRTX)

"Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
loanranger Member Profile
Member Level 
Followed By 177
Posts 29,411
Boards Moderated 0
Alias Born 06/30/09
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 7:06:47 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2020 6:04:06 AM
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/20/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/17/2020 4:07:24 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 7:32:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2020 7:08:45 AM
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 11/10/2020 7:00:00 AM
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/3/2020 8:00:00 AM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiati... GlobeNewswire Inc. - 10/27/2020 3:00:10 PM
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419... GlobeNewswire Inc. - 10/23/2020 5:00:10 PM
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with S... GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2020 5:02:22 PM
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire Inc. - 9/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2020 8:08:34 AM
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 fo... GlobeNewswire Inc. - 9/16/2020 8:00:10 AM
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire Inc. - 9/14/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2020 7:02:34 AM
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Plac... GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:11:51 AM
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 7/30/2020 8:00:10 AM
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally... GlobeNewswire Inc. - 7/13/2020 5:46:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/22/2020 4:53:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 5:48:08 PM
loanranger Member Level  Sunday, 02/02/20 10:49:30 AM
Re: None
Post # of 27 
"Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a Phase 2a clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer."

“Radiation-induced esophagitis is a common, debilitating side effect that can delay or prevent curative cancer treatment, and no FDA-approved therapies to treat it currently exist,” said Lawrence Berk, M.D., Ph.D., Professor of Radiation Oncology at the University of South Florida and lead investigator of the Phase 2a trial.

"Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication"

https://www.globenewswire.com/news-release/2020/01/07/1967578/0/en/Galera-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-2a-Clinical-Trial-of-Avasopasem-Manganese-GC4419-in-Second-Indication.html

But can it core A apple?
Yes Ralph, of course it can core A apple.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences